My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

149.44 +6.13 (+4.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

2 Monster Stocks in the Making ↗

November 10, 2025

There might still be time to get in on the ground floor.

Via The Motley Fool

Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗

November 03, 2025

Axsome Therapeutics Q3 2025 results: Revenue beat expectations with strong product sales, but the company reported a wider-than-expected loss.

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Uncovering Potential: Axsome Therapeutics's Earnings Preview ↗

October 31, 2025

Via Benzinga

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗

September 30, 2025

Both should have significant catalysts by the end of the decade.

Via The Motley Fool

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Where Axsome Therapeutics Stands With Analysts ↗

August 04, 2025

Via Benzinga

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

A Look at Axsome Therapeutics's Upcoming Earnings Report ↗

August 01, 2025

Via Benzinga

Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗

September 04, 2025

Both companies have made significant progress in recent years.

Via The Motley Fool

A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 8 Analysts ↗

September 03, 2025

Via Benzinga

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years ↗

August 18, 2025

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.

Via Benzinga

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings ↗

August 05, 2025

Via Benzinga

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading ↗

August 04, 2025

Axsome Therapeutics beats Q2 2025 revenue estimates with $150M, driven by Auvelity's 84% YoY growth. Shares rise 6% pre-market on improved EPS.

Via Chartmill

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Axsome (AXSM) Q2 Revenue Soars 72% ↗

August 04, 2025

Via The Motley Fool

Topics Intellectual Property

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now ↗

July 24, 2025

Via The Motley Fool

Where Axsome Therapeutics Stands With Analysts ↗

July 03, 2025

Via Benzinga

FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required ↗

June 09, 2025

The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028.

Via Benzinga

Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews ↗

June 09, 2025

Via Benzinga

Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability ↗

June 09, 2025

The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.

Via Stocktwits

Topics Stocks

2 Soaring Stocks Wth More Upside Potential ↗

June 05, 2025

Via The Motley Fool

Why Is Teva Stock Trading Higher On Tuesday? ↗

May 27, 2025

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Via Benzinga

3 High-Flying Stocks That Could Soar Even More ↗

May 24, 2025

Via The Motley Fool

Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts ↗

May 22, 2025

Via Benzinga

Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis ↗

May 14, 2025

Via The Motley Fool

Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years ↗

May 12, 2025

Via The Motley Fool

3 Monster Stocks in the Making ↗

May 11, 2025

Via The Motley Fool

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1 ↗

May 05, 2025

Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs.

Via Benzinga

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗

April 29, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.